↓ Skip to main content

Angiosarcoma treated successfully with anti-PD-1 therapy - a case report

Overview of attention for article published in Journal for Immunotherapy of Cancer, July 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)

Mentioned by

14 tweeters
1 Facebook page


75 Dimensions

Readers on

64 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report
Published in
Journal for Immunotherapy of Cancer, July 2017
DOI 10.1186/s40425-017-0263-0
Pubmed ID

Simran Sindhu, Lana H. Gimber, Lee Cranmer, Ali McBride, Andrew S. Kraft


Angiosarcomas are tumors of malignant endothelial origin that have a poor prognosis with a five-year survival of less than 40%. These tumors can be found in all age groups, but are more common in older patients; with the cutaneous form most common in older white men. Combined modality therapy including surgery and radiation appears to have a better outcome than each modality alone. When metastatic, agents such as liposomal doxorubicin, paclitaxel and ifosfamide have activity but it is short-lived and not curative. Immunotherapy targeting either the PD-1 receptor or PD-L1 ligand has recently been shown to have activity in multiple cancers including melanoma, renal, and non-small lung cancer. Although these agents have been used in sarcoma therapy, their ability to treat angiosarcoma has not been reported. Here we describe the case of a 63-year-old man who presented initially with angiosarcoma of the nose and received surgery for the primary. Over 4 years he had recurrent disease in the face and liver and was treated with nab-paclitaxel, surgery, and radioembolization, but continued to have progressive disease. His tumor was found to express PD-L1 and he received off-label pembrolizumab 2 mg/kg every 21 days for 13 cycles with marked shrinkage of his liver disease and no new facial lesions. Secondary to this therapy he developed hepatitis and has been treated with decreasing doses of prednisone. During the 8 months off therapy he has developed no new or progressive lesions. Although occasional responses to immunotherapy have been reported for sarcomas, this case report demonstrates that angiosarcoma can express PD-L1 and have a sustained response to PD-1 directed therapy.

Twitter Demographics

The data shown below were collected from the profiles of 14 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 64 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 20%
Student > Master 10 16%
Other 9 14%
Student > Ph. D. Student 5 8%
Student > Postgraduate 4 6%
Other 12 19%
Unknown 11 17%
Readers by discipline Count As %
Medicine and Dentistry 34 53%
Biochemistry, Genetics and Molecular Biology 3 5%
Pharmacology, Toxicology and Pharmaceutical Science 3 5%
Agricultural and Biological Sciences 1 2%
Psychology 1 2%
Other 3 5%
Unknown 19 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 August 2018.
All research outputs
of 16,945,511 outputs
Outputs from Journal for Immunotherapy of Cancer
of 1,635 outputs
Outputs of similar age
of 272,243 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
of 1 outputs
Altmetric has tracked 16,945,511 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,635 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.0. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 272,243 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them